A Phase I-IIa Study of Safety, Tolerance, Pharmacokinetics, Dosimetry and Benefice of Early Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis

Trial Profile

A Phase I-IIa Study of Safety, Tolerance, Pharmacokinetics, Dosimetry and Benefice of Early Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Tc-99m annexin V 128 (Primary)
  • Indications Ankylosing spondylitis; Rheumatoid arthritis
  • Focus Adverse reactions; Diagnostic use
  • Sponsors Advanced Accelerator Applications
  • Most Recent Events

    • 26 Oct 2017 Status changed from recruiting to discontinued.
    • 10 Jun 2017 Biomarkers information updated
    • 23 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top